Clinical trial
Effect of PCSK9-Antibody (Alirocumab) on Dyslipidemia Secondary to Nephrotic Syndrome
NCT03004001 is registered in ClinicalTrials.gov with Gloria Vega as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Effect of PCSK9-Antibody (Alirocumab) on Dyslipidemia Secondary to Nephrotic Syndrome
- Lead sponsor
- Gloria Vega
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- January 31, 2017
- Completion date
- December 31, 2019
- Enrollment
- 3 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.